For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230314:nRSN9635Sa&default-theme=true
RNS Number : 9635S MyCelx Technologies Corporation 14 March 2023
14 March 2023
MYCELX TECHNOLOGIES CORPORATION (AIM: MYX)
Closure of Restricted Stock Line
MYCELX Technologies Corporation ("MYCELX" or the "Company"), the clean water
and clean air technology company, confirms the closure of its restricted line
of stock will take effect at 8.00 a.m. on 22 March 2023.
Application has been made to the London Stock Exchange for the transfer of an
additional 3,539,273 common shares of $0.25 each ("Common Shares") (the
"Additional Shares") from the Company's restricted line of stock with the
ticker MYXR (identified under ISIN USU624551235) (the "Restricted Line") to
the Company's unrestricted line of stock with the ticker MYX (identified under
ISIN US62847T2024) (the "Unrestricted Line").
The Additional Shares are constituted of 3,539,273 Common Shares which have
been transferred upon expiry of the restricted period under Regulation S of
the US Securities Act of 1933.
Trading in the Company's Restricted Line will cease at 8.00 a.m. on 22 March
2023 and all Common Shares currently trading on the Restricted Line will from
then on continue to trade on the Unrestricted Line. Certificated holders will
also be issued a replacement share certificate, representing their new holding
in unrestricted shares.
The Company's issued share capital consists of 22,983,023 Common Shares with
no Common Shares held in treasury. Therefore, the total number of voting
rights in the Company is 22,983,023 which may be used by shareholders as the
denominator for the calculations by which they determine if they are required
to notify their interest in, or a change to their interest in, the Company
under the Financial Conduct Authority's Disclosure Guidance and Transparency
Rules.
From 22 March 2023, all of the 22,983,023 Common Shares will be admitted to
trading on the Unrestricted Line.
For further information, please contact:
MYCELX Technologies Corporation
Connie Mixon, CEO Tel: +1 888 306 6843
Kim Slayton, CFO
Canaccord Genuity Limited (Nomad and Sole Broker)
Henry Fitzgerald-O'Connor Tel: +44 20 7523 8000
Gordon Hamilton
Celicourt Communications (Financial PR)
Mark Antelme Tel: +44 20 8434 2754
Jimmy Lea
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END MSCJIMFTMTIBBTJ